drugset / Trial / NCT05951296
A Study to Investigate Leramistat in Patients With IPF
RandomizedParallel-groupDouble-blindTreatment
Summary
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2023-08-30
- Primary completion
- 2024-02-27
- Completion
- 2024-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leramistat | Small molecule | — | Oral |